<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Sequencing Treatment in Third-Line R/R LBCL: Insights from ASH 2024

by CGTLive | January 10, 2025
placeholder

CU Cancer Center member Manali Kamdar, MD, clinical director of lymphoma services, explores sequencing options for third-line relapsed/refractory large B-cell lymphoma (LBCL). She highlights the curative potential of liso-cel and the convenience of CD20 BiTEs, offering insights into their respective benefits and challenges.

Topics: Press Coverage